SINGAPORE (June 25): Medical technology company Biolidics has entered into a partnership with Zhongshan TopGene Medical Laboratory Co to develop and commercialise laboratory-developed tests (LDTs) in the field of circulating tumour cells (CTCs) using Biolidics' ClearCell FX1 System and CTChip FR1 biochip.

Certified and licensed to undertake clinical trials in China, Zhongshan TopGene is a wholly-owned subsidiary of TopGene Tech (Guangzhou) Co which specialises in the diagnosis and treatment of cancer in the country.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.

Bonus:

  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply

Subscribe

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook